T1	DISO 1276 1281	CVNMI
T2	CHEM 66 75	nivolumab
#1	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 78 81	BCG
#2	AnnotatorNotes T3	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T4	CHEM 99 102	BCG
#3	AnnotatorNotes T4	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T5	PROC 106 117	monoterapia
#4	AnnotatorNotes T5	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T6	DISO 124 159	cáncer de vejiga no musculoinvasivo
T7	PROC 197 237	Ensayo fase 3, aleatorizado, doble ciego
T8	CHEM 242 251	nivolumab
#5	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 271 274	BCG
#6	AnnotatorNotes T9	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T10	CHEM 327 330	BCG
#7	AnnotatorNotes T10	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T11	PROC 334 345	monoterapia
#8	AnnotatorNotes T11	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T12	DISO 363 398	cáncer de vejiga no musculoinvasivo
T13	CHEM 475 478	BCG
#9	AnnotatorNotes T13	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T14	DISO 502 518	Cáncer de vejiga
#10	AnnotatorNotes T14	C0005684; Malignant neoplasm of urinary bladder; Neoplastic Process
T15	DISO 595 616	CU no musculoinvasivo
T16	DISO 724 727	CIS
#11	AnnotatorNotes T16	C0007099; Carcinoma in Situ; Neoplastic Process | C0851135; In situ cancer; Neoplastic Process
T17	PROC 732 743	Tratamiento
#12	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	CHEM 791 794	BCG
#13	AnnotatorNotes T18	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T19	DISO 1041 1049	cánceres
#14	AnnotatorNotes T19	C0006826; Malignant Neoplasms; Neoplastic Process
T20	PROC 1124 1135	tratamiento
#15	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	DISO 1153 1171	trastornos médicos
T22	DISO 1221 1242	enfermedad autoinmune
#16	AnnotatorNotes T22	C0004364; Autoimmune Diseases; Disease or Syndrome
T23	CHEM 1348 1351	BCG
#17	AnnotatorNotes T23	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T24	CHEM 1399 1402	BCG
#18	AnnotatorNotes T24	C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T25	PROC 547 583	Consentimiento informado por escrito
#19	AnnotatorNotes T25	C0811741; Obtain informed written consent; Health Care Activity
T26	DISO 1441 1453	tuberculosis
#20	AnnotatorNotes T26	C0041296; Tuberculosis; Disease or Syndrome
T27	ANAT 134 140	vejiga
#21	AnnotatorNotes T27	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T28	PROC 298 323	tratamiento de referencia
T29	ANAT 373 379	vejiga
#22	AnnotatorNotes T29	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T30	PROC 459 470	tratamiento
#23	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	ANAT 512 518	vejiga
#24	AnnotatorNotes T31	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T32	DISO 982 992	Malignidad
#25	AnnotatorNotes T32	C0006826; Malignant Neoplasms; Neoplastic Process
T33	PROC 777 786	inducción
#26	AnnotatorNotes T33	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T34	PROC 1387 1394	terapia
#27	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	Date 13 17	2019
T36	Route 82 94	intravesical
T38	Route 275 287	intravesical
T39	LIVB 349 358	pacientes
#28	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T44	Dose 796 817	al menos 5 de 6 dosis
T46	LIVB 905 912	mujeres
#29	AnnotatorNotes T46	C0043210; Woman; Population Group
T47	Age 914 930	de 18 años o más
T48	Duration 1010 1031	los 3 años anteriores
T49	Neg_cue 1033 1040	excepto
T50	Neg_cue 1111 1113	no
T51	LIVB 1139 1148	Pacientes
#30	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T53	Spec_cue 1262 1272	sospechada
T56	Route 1403 1415	intravesical
T37	Age 937 952	mayoría de edad
T40	LIVB 1199 1212	Participantes
#31	AnnotatorNotes T40	C4554048; Study Participant; Population Group
T41	LIVB 895 902	Varones
#32	AnnotatorNotes T41	C0025266; Male population group; Population Group
T42	PROC 822 838	Estado funcional
#33	AnnotatorNotes T42	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T43	PROC 629 645	histológicamente
#34	AnnotatorNotes T43	C0344441; Histology Procedure; Laboratory Procedure
A1	Assertion T19 Negated
A2	Assertion T20 Negated
A3	Assertion T22 Speculated
A4	Status T22 History_of
A5	Assertion T34 Contraindicated
A6	Assertion T24 Contraindicated
A7	Status T32 History_of
A8	Status T19 History_of
A9	Status T33 History_of
A10	Status T18 History_of
A11	Status T17 History_of
A12	Status T30 History_of
A13	Status T13 History_of
#35	AnnotatorNotes T7	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#36	AnnotatorNotes T36	C1522448; Intravesical Route of Drug Administration; Functional Concept 
#37	AnnotatorNotes T38	C1522448; Intravesical Route of Drug Administration; Functional Concept 
#38	AnnotatorNotes T56	C1522448; Intravesical Route of Drug Administration; Functional Concept 
#39	AnnotatorNotes T21	C0012634; Disease; Disease or Syndrome
T45	Neg_cue 1332 1335	sin
T52	Observation 1336 1345	respuesta
A14	Assertion T52 Negated
#40	AnnotatorNotes T52	C4055223; Clinical Response; Finding (?)
T54	Quantifier_or_Qualifier 1050 1069	curables localmente
A15	Assertion T54 Negated
R1	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T54	
T55	Observation 1074 1104	aparentemente han sido curados
A16	Assertion T55 Negated
R2	Negation Arg1:T49 Arg2:T19	
R3	Negation Arg1:T50 Arg2:T20	
R4	Negation Arg1:T49 Arg2:T54	
R5	Negation Arg1:T49 Arg2:T55	
T57	Neg_cue 1181 1183	no
T58	Quantifier_or_Qualifier 1184 1195	controlados
A17	Assertion T58 Negated
R6	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T58	
R7	Negation Arg1:T57 Arg2:T58	
R8	Speculation Arg1:T53 Arg2:T22	
R9	Negation Arg1:T45 Arg2:T52	
T59	Quantifier_or_Qualifier 1172 1178	graves
#41	AnnotatorNotes T59	C1547227;Severe - Severity of Illness Code; Intellectual Product
R10	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T59	
R11	Overlap Arg1:T32 Arg2:T48	
T60	Quantifier_or_Qualifier 993 999	activa
#42	AnnotatorNotes T60	C0679217;Active State; Idea or Concept
T61	Quantifier_or_Qualifier 1243 1249	activa
#43	AnnotatorNotes T61	C0679217;Active State; Idea or Concept
R12	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T60	
R13	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T61	
T62	Quantifier_or_Qualifier 1454 1460	activa
#44	AnnotatorNotes T62	C0679217;Active State; Idea or Concept
R14	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T62	
R15	Has_Route_or_Mode Arg1:T24 Arg2:T56	
R16	Used_for Arg1:T24 Arg2:T34	
R17	Has_Route_or_Mode Arg1:T3 Arg2:T36	
R18	Has_Route_or_Mode Arg1:T2 Arg2:T36	
R19	Used_for Arg1:T4 Arg2:T5	
R20	Location_of Arg1:T27 Arg2:T6	
T63	Observation 144 159	musculoinvasivo
A18	Assertion T63 Negated
#45	AnnotatorNotes T63	C4725840; Muscle Invasion; Finding
T64	Neg_cue 141 143	no
R21	Negation Arg1:T64 Arg2:T63	
T65	Neg_cue 380 382	no
T66	Observation 383 398	musculoinvasivo
A19	Assertion T66 Negated
#46	AnnotatorNotes T66	C4725840; Muscle Invasion; Finding
R22	Negation Arg1:T65 Arg2:T66	
R25	Location_of Arg1:T29 Arg2:T12	
R26	Location_of Arg1:T31 Arg2:T14	
T67	Observation 163 174	alto riesgo
#47	AnnotatorNotes T67	C4319571; High risk; Finding
R27	Combined_with Arg1:T8 Arg2:T9	
R28	Has_Route_or_Mode Arg1:T9 Arg2:T38	
R29	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T67	
T68	Observation 402 413	alto riesgo
#48	AnnotatorNotes T68	C4319571; High risk; Finding
R30	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T68	
R31	Experiences Arg1:T39 Arg2:T30	
R32	Experiences Arg1:T39 Arg2:T8	
R33	Experiences Arg1:T39 Arg2:T28	
R34	Used_for Arg1:T10 Arg2:T28	
R35	Used_for Arg1:T10 Arg2:T11	
R36	Used_for Arg1:T13 Arg2:T30	
T69	Quantifier_or_Qualifier 421 432	persistente
#49	AnnotatorNotes T69	C0205322; Persistent; Temporal Concept
R37	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T69	
R38	After Arg1:T69 Arg2:T30	
T70	Observation 435 446	recidivante
#50	AnnotatorNotes T70	C2825055; Recurrence (disease attribute); Pathologic Function
R39	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T70	
R40	After Arg1:T70 Arg2:T30	
R41	Experiences Arg1:T39 Arg2:T12	
T71	Neg_cue 598 600	no
T72	Observation 601 616	musculoinvasivo
A20	Assertion T72 Negated
#51	AnnotatorNotes T72	C4725840; Muscle Invasion; Finding
R44	Negation Arg1:T71 Arg2:T72	
T73	Observation 676 687	alto riesgo
#52	AnnotatorNotes T73	C4319571; High risk; Finding
R48	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T73	
T74	Quantifier_or_Qualifier 647 658	persistente
#53	AnnotatorNotes T74	C0205322; Persistent; Temporal Concept
R49	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T74	
T75	Observation 661 671	recurrente
#54	AnnotatorNotes T75	C2825055; Recurrence (disease attribute); Pathologic Function
R50	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T75	
T76	Observation 689 705	Ta de alto grado
T77	Observation 707 711	TaAG
T78	Observation 717 719	T1
#55	AnnotatorNotes T78	C0475372; Tumor stage T1; Finding
R51	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T76	
R52	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T77	
R53	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T78	
T79	Quantifier_or_Qualifier 748 764	al menos 1 ciclo
R54	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T79	
R55	Used_for Arg1:T18 Arg2:T33	
R56	Used_for Arg1:T18 Arg2:T17	
R57	Has_Dose_or_Strength Arg1:T18 Arg2:T44	
T80	Result_or_Value 888 891	0-2
T81	CONC 879 883	ECOG
#56	AnnotatorNotes T81	C1520224; ECOG performance status; Intellectual Product
T82	CONC 843 877	Eastern Cooperative Oncology Group
#57	AnnotatorNotes T82	C1520224; ECOG performance status; Intellectual Product
R58	Used_for Arg1:T82 Arg2:T42	
R59	Used_for Arg1:T81 Arg2:T42	
R60	Has_Result_or_Value Arg1:T81 Arg2:T80	
R61	Has_Result_or_Value Arg1:T82 Arg2:T80	
R62	Has_Age Arg1:T41 Arg2:T47	
R63	Has_Age Arg1:T41 Arg2:T37	
R64	Has_Age Arg1:T46 Arg2:T47	
R65	Has_Age Arg1:T46 Arg2:T37	
R66	Experiences Arg1:T51 Arg2:T21	
R67	Experiences Arg1:T40 Arg2:T22	
T83	Observation 1297 1308	alto riesgo
#58	AnnotatorNotes T83	C4319571; High risk; Finding
R68	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T83	
#59	AnnotatorNotes T76	C3272501; Ta Stage Finding; Finding + C4319571; High risk; Finding
#60	AnnotatorNotes T77	C3272501; Ta Stage Finding; Finding + C4319571; High risk; Finding
T84	Observation 1282 1293	recidivante
#61	AnnotatorNotes T84	C2825055; Recurrence (disease attribute); Pathologic Function
R69	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T84	
R70	Overlap Arg1:T52 Arg2:T23	
R71	After Arg1:T84 Arg2:T23	
R72	Overlap Arg1:T1 Arg2:T52	
#62	AnnotatorNotes T28	C2936643; Standard of Care; Health Care Activity
#63	AnnotatorNotes T6	C1336527; Non-Muscle Invasive Bladder Neoplasms; Neoplastic Process
#64	AnnotatorNotes T12	C1336527; Non-Muscle Invasive Bladder Neoplasms; Neoplastic Process
#65	AnnotatorNotes T15	C1336527; Non-Muscle Invasive Bladder Neoplasms; Neoplastic Process
#66	AnnotatorNotes T1	C5418781; Non-Muscle Invasive Bladder Urothelial Carcinoma; Neoplastic Process
A21	Experiencer T51 Patient
A22	Experiencer T40 Patient
A23	Experiencer T39 Patient
A24	Experiencer T46 Patient
A25	Experiencer T41 Patient
